Abstract: In some embodiments, a set of eye images related to a subject may be provided to a prediction model. A first prediction may be obtained via the prediction model, where the first prediction is derived from a first eye image and indicates whether an eye condition is present in the subject. A second prediction may be obtained via the prediction model, where the second prediction is derived from a second eye image and indicates that the eye condition is present in the subject. An aspect associated with the first prediction may be adjusted via the prediction model based on the second prediction's indication that the eye condition is present in the subject. One or more predictions related to at least one eye condition for the subject may be obtained from the prediction model, where the prediction model generates the predictions based on the adjustment of the first prediction.

Abstract: Compositions and methods of activating dendritic cells with LMP1 and LMP1-activated dendritic cell based compositions and methods are effective for dendritic cell therapy and provide an adjuvant function for vaccine administration. LMP1 or LMP1-CD40 chimeric protein may be used to activate and mature dendritic cells. LMP1 and LMP1-activated dendritic cells act as an adjuvant to enhance the cellular immune response. Also disclosed herein are kits for activating dendritic cells and for preparing a vaccine formulation. Administration of the dendritic cells transfected with LMP1 can induce an immune response against cancer or infection. The mature dendritic cells may comprise an antigen and at least one cytokine in addition to LMP1. Use of LMP1 or LMP1-CD40 provides a way to activate and mature dendritic cells that retain functional and migratory abilities without the side effects that result from maturing the dendritic cells using PGE2.

Abstract: Kits and methods for detecting pathogens without the need for laboratory equipment are disclosed. The kits and methods described herein allow for near-room temperature amplification of pathogen polynucleotides in a biological sample in a one-compartment reaction vessel. The kits and methods may be used to detect any target nucleic acid, such as DNA or RNA from a bacterial, fungal, or viral pathogen.

Abstract: In certain embodiments, image data modifications may be facilitated for dynamic vision defects. In some embodiments, one or more eyes of a user may be monitored while a set of stimuli are displayed to the user. Feedback related to the set of stimuli may be obtained, where the feedback indicates (i) whether or how the user sees one or more stimuli of the set or (ii) one or more characteristics related to the eyes that occurred when such stimuli are displayed. A set of modification profiles associated with the user may be generated based on the feedback, where each modification profile of the set (i) is associated with eye-related characteristics and (ii) includes modification parameters to be applied to an image to modify the image for the user when eye-related characteristics of the user matches the associated eye-related characteristics.

Abstract: The invention provides fusion proteins comprising antigens of infectious disease agents and cancer cells linked to multiple-trimer forms of TNF SuperFamily (TNFSF) ligands. The TNFSFs serve as vaccine adjuvants for increasing the immune response to the antigens. In particular, a fusion polypeptide strand that self-assembles inside cells into a multiple-trimer form of CD40 ligand (CD40L, TNFSF5) is provided. Other similar fusion proteins are also disclosed. The fusion proteins can be delivered to a host as isolated proteins, as nucleic acids used directly in DNA vaccination or carried and expressed by a viral vector such as adenovirus. In addition to use as a vaccine to prevent or ameliorate disease caused by an infectious agent, compositions of the invention may be used for the treatment of ongoing infection or for cancer immunotherapy.

Abstract: A general method of analyzing immune signaling networks for identification of potential therapeutic targets in complex, chronic medical disorders is described. The disclosure provides the CD3?/CD56+ natural killer (NK) cell population as a potential therapeutic target in the clinically-overlapping disorders Gulf War Illness (GWI) and Myalg Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The disclosure also provides a method for improving or restoring Natural Killer (NK) cell function by stimulating the NK cells with interleukin-15 (IL-15).

Abstract: In certain embodiments, double-vision-related vision defects determinations or modifications may be facilitated. In some embodiments, a stimulus may be to be presented at a first time at a position on a first display for a deviating eye of a user (e.g., without a stimulus being presented on a second display of for a reference eye of the user) to cause the deviating eye to fixate on the position on the first display. A deviation measurement for the deviating eye may be determined based on an amount of movement of the deviating eye occurring upon the presentation on the first display for the deviating eye at the first time. In some embodiments, a modification profile associated with the user may be determined based on the deviation measurement, where the modification profile includes one or more modification parameters to be applied to modify an image for the user.

Abstract: The compositions and methods described herein include agents that inhibit inflammasome signaling in the mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s). Also described herein are compositions and methods of use thereof for treating multiple sclerosis.

Abstract: The present invention relates, in part, to methods of generating immune responses in subjects that have a likelihood of developing cancer.

Abstract: The disclosure relates to test kits and methods for detecting the presence of Coronavirus polynucleotides in a biological sample.

Abstract: Devices and methods of making and using the device for the non-invasive detection of volatile anesthetics are provided. The devices are capable of measuring the concentration of volatile anesthetics transdermally and in a non-invasive manner. The devices and methods can be applied in detection of volatile anesthetics in samples collected from human skin perspiration.

Abstract: In certain embodiments, a user's field of view may be increased and/or modified. In some embodiments, views of a scene may be obtained via a wearable device. A first region of the scene may be determined, where the first region is common to the views and represented in the views at proximate a center of each of the views. For each view of the views, a second region of the scene may be determined, where the second region is represented in the view and related to peripheral vision of the user. A modified view may be generated based on (i) a portion of at least one of the views that corresponds to the common first region and (ii) portions of the views that correspond to the second regions such that the modified view comprises a representation of the common first region and representations of the second regions.

Abstract: In certain embodiments, vision-related alerting may be facilitated based on a physical contact prediction. In some embodiments, a prediction indicating defective visual field portions of a user's visual field may be generated based on feedback related to a set of stimuli displayed to the user. The defective visual field portions may be visual field portions of the visual field that fail to satisfy one or more vision criteria. Based on the prediction of the defective visual field portions, a modified video stream derived from a live video stream to be presented via a wearable device. Activation of an alert may be caused via the wearable device based on (i) a prediction of physical contact (of an object with the user) and (ii) the object not being sufficiently in any image portion of the modified video stream that corresponds to at least one visual field portion satisfying the vision criteria.

Abstract: This document provides novel compositions and methods utilizing immunomodulating agents that can stimulate or indirectly augment the immune system, or can have an immunosuppressive effect. TNFR25 agonists disclosed herein have an anti-inflammatory and healing effect. They can be used, e.g., to treat disease caused by asthma and chronic inflammation, such as inflammatory bowel diseases including ulcerative colitis and Crohn's Disease. TNFR25 antagonists disclosed herein can inhibit CD8 T cell-mediated cellular immune responses and can, for example, mitigate organ or tissue rejection following a tissue transplantation. TNFR25 agonists disclosed herein represent biological response modifiers that alter the interaction between the body's cellular immune defenses and cancer cells to boost, direct, or restore the body's ability to fight the cancer when given with tumor vaccines.

Abstract: Sodium cellulose sulfate (NaCS) is employed as a novel GAG mimetic. Schwann cells (SCs) could be used in combination with a scaffold because the SCs can secrete neurotrophic factors stimulating neuron survival and extension of axons. Furthermore, the conduit may be used alone or combination with Schwann cells for spinal cord repair. In addition, the conduit also can be used for peripheral nerve repair. Also described herein are compositions and methods useful for promoting the growth and/or differentiation and/or repair of a cell and/or tissue in the peripheral nervous system, central nervous system, and specifically the spinal cord. In certain aspects, the present disclosure includes a scaffold supporting and promoting growth, differentiation, and/or regeneration and repair. The scaffold in one embodiment closely mimics the natural extracellular matrix (ECM) of the spinal cord.

Abstract: Described herein are nanoparticle-based compositions, kits and methods and platforms for delivering one or more nucleic acids to a myeloid cell.

Abstract: Disclosed herein are inhibitors of TNF superfamily costimulatory interactions, and methods for their use in modulating TNF superfamily costimulatory interactions and treating immune system related disorders. In particular, disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof: wherein the substituents are described herein.

Abstract: Disclosed herein are compositions of GHRH agonists and peptides, and methods to treat disorders, such as ischemia and reperfusion injury. In one embodiment, a method of treating a reperfusion injury in a subject in need may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In additional embodiment, a method of promoting vasculogenesis in a mammal may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In a further embodiment, a method of promoting differentiation of mesenchymal stem cells into endothelial cells may involve contacting mesenchymal stem cells with at least one GHRH agonist peptide.

Abstract: In certain embodiments, vision defect information may be generated via a dynamic eye-characteristic-based fixation point. In some embodiments, a first stimulus may be displayed at a first location on a user interface based on a fixation point for a visual test presentation. The fixation point for the visual test presentation may be adjusted during the visual test presentation based on eye characteristic information related to a user. As an example, the eye characteristic information may indicate a characteristic of an eye of the user that occurred during the visual test presentation. A second stimulus may be displayed during the visual test presentation at a second interface location on the user interface based on the adjusted fixation point for the visual test presentation. Vision defect information associated with the user may be generated based on feedback information indicating feedback related to the first stimulus and feedback related to the second stimulus.